公开(公告)号：WO2011044570A3

公开(公告)日：2011-09-29

申请号：PCT/US2010052274

申请日：2010-10-12

Applicant: UNIV EMORY ,  UNIV CHICAGO ,  WRAMMERT JENS ,  AHMED RAFI ,  WILSON PATRICK

Inventor： WRAMMERT JENS ,  AHMED RAFI ,  WILSON PATRICK

IPC: C07K16/10 ,  A61K39/42 ,  A61P31/16 ,  C12N15/13

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76

Abstract: Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.

Abstract translation: 描述了以高亲和力结合猪H1N1病毒的抗体。 体内实验表明，一种这样的抗体能够完全保护用致死剂量的猪H1N1病毒攻击的小鼠。 当用猪H1N1病毒感染后，抗体还能治疗至少长达60小时（2.5天）的治疗环境中的小鼠。 还描述了该抗体的重组形式。

公开(公告)号：WO2010036959A3

公开(公告)日：2010-04-01

申请号：PCT/US2009/058475

申请日：2009-09-25

Applicant: DANA-FARBER CANCER INSTITUTE ,  EMORY UNIVERSITY ,  FREEMAN, Gordon ,  AHMED, Rafi ,  JONES, Timothy, D. ,  CARR, Francis, J. ,  GREGSON, James, P.

Inventor： FREEMAN, Gordon ,  AHMED, Rafi ,  JONES, Timothy, D. ,  CARR, Francis, J. ,  GREGSON, James, P.

IPC: C07K16/18 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00

Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity ( e.g. , persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

公开(公告)号：WO2006133396A2

公开(公告)日：2006-12-14

申请号：PCT/US2006/022423

申请日：2006-06-08

Applicant: DANA-FARBER CANCER INSTITUTE ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  EMORY UNIVERSITY ,  FREEMON, Gordon ,  SHARPE, Arlene ,  DORFMAN, David, M. ,  AHMED, Rafi ,  BARBER, Daniel ,  WHERRY, E., John

Inventor： FREEMON, Gordon ,  SHARPE, Arlene ,  DORFMAN, David, M. ,  AHMED, Rafi ,  BARBER, Daniel ,  WHERRY, E., John

CPC classification number: C07K16/2803 ,  A61K31/713 ,  A61K38/1709 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/572 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/5011 ,  G01N33/505 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2800/26 ,  Y02A50/412 ,  Y02A50/467 ,  Y02A50/58

Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

Abstract translation: 本发明提供用于治疗，预防或减少持续感染例如慢性感染，潜伏感染，慢感染和癌症的方法和组合物。 本发明的方法和组合物还可用于缓解与这种感染和癌症相关的一种或多种症状。

公开(公告)号：WO2010060051A2

公开(公告)日：2010-05-27

申请号：PCT/US2009/065563

申请日：2009-11-23

Applicant: EMORY UNIVERSITY ,  PULEDRAN, Bali ,  AHMED, Rafi ,  LEE, Eva ,  QUEREC, Troy

Inventor： PULEDRAN, Bali ,  AHMED, Rafi ,  LEE, Eva ,  QUEREC, Troy

IPC: C12Q1/70

CPC classification number: C12Q1/6876 ,  C12Q2600/158 ,  Y02A50/60

Abstract: A major challenge in vaccinology is to prospectively determine vaccine efficacy. Disclosed herein are methods and compositions for identifying early expression "signatures" that predicted immune responses in humans vaccinated with a vaccine.

Abstract translation: 疫苗学的一个主要挑战是前瞻性地确定疫苗功效。 本文公开了用于鉴定预测用疫苗接种的人中的免疫应答的早期表达“签名”的方法和组合物。

公开(公告)号：WO2010017317A2

公开(公告)日：2010-02-11

申请号：PCT/US2009/052886

申请日：2009-08-05

Applicant: EMORY UNIVERSITY ,  AHMED, Rafi ,  LARSEN, Christian, P. ,  ARAKI, Koichi

Inventor： AHMED, Rafi ,  LARSEN, Christian, P. ,  ARAKI, Koichi

IPC: A61K31/4745 ,  A61P35/00 ,  A61P31/12

CPC classification number: A61K31/436 ,  A61K31/4745 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55561 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2730/10134 ,  C12N2740/13023 ,  C12N2740/13043 ,  C12N2760/10034 ,  C12N2770/10022 ,  A61K2300/00

Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.

Abstract translation: 本文公开了用mTOR抑制剂治疗受试者增强抗原特异性T细胞免疫应答。 因此，本文提供了通过向受试者施用治疗有效量的mTOR抑制剂来增强受试者中抗原特异性T细胞应答的方法。 抗原可以是任何抗原，例如来自病原体或疫苗的抗原或肿瘤抗原。 在一些实施方案中，该方法还包括向受试者施用疫苗，例如病毒疫苗或癌症疫苗。 mTOR抑制剂可以在接种之前或之后施用以增强T细胞免疫应答和免疫记忆的数量和质量。 在一些实例中，mTOR抑制剂是雷帕霉素或雷帕霉素类似物。

公开(公告)号：WO2006133396A3

公开(公告)日：2007-08-09

申请号：PCT/US2006022423

申请日：2006-06-08

Applicant: DANA FARBER CANCER INST INC ,  BRIGHAM & WOMENS HOSPITAL ,  UNIV EMORY ,  FREEMAN GORDAN ,  SHARPE ARLENE ,  DORFMAN DAVID M ,  AHMED RAFI ,  BARBER DANIEL ,  WHERRY E JOHN

Inventor： FREEMAN GORDAN ,  SHARPE ARLENE ,  DORFMAN DAVID M ,  AHMED RAFI ,  BARBER DANIEL ,  WHERRY E JOHN

IPC: A61K39/395 ,  C07K16/28 ,  G01N33/53

CPC classification number: C07K16/2803 ,  A61K31/713 ,  A61K38/1709 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/572 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/5011 ,  G01N33/505 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2800/26

Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

Abstract translation: 本发明提供用于治疗，预防或减少持续感染例如慢性感染，潜伏感染，慢感染和癌症的方法和组合物。 本发明的方法和组合物还可用于缓解与这种感染和癌症相关的一种或多种症状。

公开(公告)号：WO0021558A9

公开(公告)日：2001-05-25

申请号：PCT/US9923477

申请日：1999-10-08

Applicant: BIOGEN INC ,  UNIV EMORY ,  BROWNING JEFF ,  PUGLIELLI MARYANN ,  AHMED RAFI

Inventor： BROWNING JEFF ,  PUGLIELLI MARYANN ,  AHMED RAFI

IPC: A61K45/00 ,  A61K38/00 ,  A61K38/17 ,  A61K38/19 ,  A61K38/22 ,  A61K39/395 ,  A61P31/12 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K16/241 ,  A61K38/1793 ,  A61K38/191 ,  A61K2039/505 ,  C07K16/242 ,  C07K16/2866 ,  C07K2319/30

Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

Abstract translation: 本发明提供在个体中诱导抗病毒应答的方法，包括向个体施用有效量的LT-B封闭剂和药学上可接受的载体。 特别地，本发明提供了治疗病毒诱导的全身性休克和呼吸窘迫的方法。

公开(公告)号：WO2010063011A3

公开(公告)日：2010-10-14

申请号：PCT/US2009066023

申请日：2009-11-27

Applicant: UNIV EMORY ,  DANA FARBER CANCER INST INC ,  AHMED RAFI ,  AMARA RAMA ,  VELU VIJAYAKUMAR ,  TITANJI KEHMIA ,  FREEMAN GORDON

Inventor： AHMED RAFI ,  AMARA RAMA ,  VELU VIJAYAKUMAR ,  TITANJI KEHMIA ,  FREEMAN GORDON

IPC: C12Q1/02 ,  A61K31/7105 ,  A61P35/00 ,  C12N5/0781 ,  G01N33/15

CPC classification number: G01N33/5052 ,  A61K31/7105 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K39/39541 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55516 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2760/10034 ,  G01N33/5088 ,  G01N33/56966 ,  G01N2333/52 ,  G01N2800/26 ,  A61K2300/00

Abstract: PD-I antagonists are disclosed that can be used to reduce the expression or activity of PD-I in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-I antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-I antagonists. In addition, subjects with tumors can be treated using the PD-I antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-I antagonist. Methods are also disclosed for determining the efficacy of a PD-I antagonist in a subject administered the PD-I antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-I antagonist.

Abstract translation: 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂与来自感染剂或肿瘤的抗原可以增强特异于感染剂或肿瘤细胞的免疫应答。 因此，可以使用PD-1拮抗剂治疗患有感染的持续感染的受试者。 此外，可以使用PD-1拮抗剂治疗具有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣的抗原的活化的T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。 还公开了用于测定施用PD-1拮抗剂的受试者中PD-1拮抗剂的功效的方法。 在一些实施方案中，这些方法包括测量来自施用PD-1拮抗剂的受试者的样品中记忆B细胞的增殖。

公开(公告)号：WO2008083174A3

公开(公告)日：2008-12-18

申请号：PCT/US2007088851

申请日：2007-12-26

Applicant: UNIV EMORY ,  DANA FARBER CANCER INST INC ,  HARVARD COLLEGE ,  AHMED RAFI ,  AMARA RAMA ,  FREEMAN GORDON ,  SHARPE ARLENE

Inventor： AHMED RAFI ,  AMARA RAMA ,  FREEMAN GORDON ,  SHARPE ARLENE

IPC: C07K16/28 ,  A61K31/14 ,  A61K31/18 ,  A61K31/20 ,  A61K39/12 ,  A61K39/395

CPC classification number: C07K16/2827 ,  A61K39/12 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5158 ,  A61K2039/5256 ,  C07K16/2818 ,  C12N2710/24143 ,  C12N2740/16011 ,  C12N2760/10011 ,  C12N2760/10034 ,  C12N2770/24211 ,  A61K2300/00

Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD- 1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

Abstract translation: 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂与来自感染剂或肿瘤的抗原可以增强特异于感染剂或肿瘤细胞的免疫应答。 因此，可以使用PD-1拮抗剂治疗感染的受试者，例如持续感染。 此外，可以使用PD-1拮抗剂治疗具有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣的抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。

公开(公告)号：WO2017049143A1

公开(公告)日：2017-03-23

申请号：PCT/US2016/052223

申请日：2016-09-16

Applicant: DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  EMORY UNIVERSITY ,  FREEMAN, Gordon, J. ,  AHMED, Rafi ,  SHARPE, Arlene ,  HASHIMOTO, Masao ,  JIN, Hyun, Tak

Inventor： FREEMAN, Gordon, J. ,  AHMED, Rafi ,  SHARPE, Arlene ,  HASHIMOTO, Masao ,  JIN, Hyun, Tak

IPC: A61K39/395 ,  C07K19/00

CPC classification number: C07K14/70503 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2818 ,  C07K2317/73 ,  C07K2319/30

Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.

Abstract translation: 本发明涉及使用结合Fc受体的PD-1 Fc融合蛋白以及与之相关的诊断，预后，治疗方法和组合物来减少表达肝脏PD-1的CD8 + T细胞的方法。